Presentation of HIV-1 Envelope Trimers on the Surface of Silica Nanoparticles.
AIDS Vaccines
/ chemistry
Adsorption
Animals
Antibodies, Neutralizing
/ metabolism
Antibody Affinity
Binding Sites, Antibody
Cells, Cultured
Dendritic Cells
/ metabolism
Drug Carriers
Drug Compounding
HIV Envelope Protein gp120
/ chemistry
HIV Envelope Protein gp41
/ chemistry
Male
Mice, Inbred C57BL
Nanoparticles
Nanotechnology
Proof of Concept Study
Protein Multimerization
Protein Structure, Quaternary
Silicon Dioxide
/ chemistry
Surface Properties
HIV/AIDS
envelope
nanoparticle(s)
protein delivery
silica
vaccine delivery
Journal
Journal of pharmaceutical sciences
ISSN: 1520-6017
Titre abrégé: J Pharm Sci
Pays: United States
ID NLM: 2985195R
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
11
08
2019
revised:
19
09
2019
accepted:
25
10
2019
pubmed:
5
11
2019
medline:
25
3
2021
entrez:
5
11
2019
Statut:
ppublish
Résumé
Inducing immune responses protecting from HIV infection or at least controlling replication poses a huge challenge to modern vaccinology. An increasingly discussed strategy to elicit a potent and broad neutralizing antibody response is the immobilization of HIV's trimeric envelope (Env) surface receptor on a nanoparticulate carrier. As a conceptual proof, we attached an Env variant (BG505 SOSIP.664) to highly stable and biocompatible silica nanoparticles (SiNPs) via site-specific covalent conjugation or nonspecific adsorption to SiNPs. First, we demonstrated the feasibility of SiNPs as platform for Env presentation by a thorough characterization process during which Env density, attachment stability, and antigenicity were evaluated for both formulations. Binding affinities to selected antibodies were in the low nanomolar range for both formulations confirming that the structural integrity of Env is retained after attachment. Second, we explored the recognition of SiNP conjugates by antigen presenting cells. Here, the uptake of Env attached to SiNPs via a site-specific covalent conjugation was 4.5-fold enhanced, whereas adsorbed Env resulted only in a moderate 1.4-fold increase compared with Env in its soluble form. Thus, we propose SiNPs with site-specifically and covalently conjugated Env preferably in a high density as a promising candidate for further investigations as vaccine platform.
Identifiants
pubmed: 31682830
pii: S0022-3549(19)30731-2
doi: 10.1016/j.xphs.2019.10.059
pii:
doi:
Substances chimiques
AIDS Vaccines
0
Antibodies, Neutralizing
0
Drug Carriers
0
HIV Envelope Protein gp120
0
HIV Envelope Protein gp41
0
gp120 protein, Human immunodeficiency virus 1
0
gp41 protein, Human immunodeficiency virus 1
0
Silicon Dioxide
7631-86-9
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
911-921Informations de copyright
Copyright © 2020 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.